Ernest Mario Sells 10,000 Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Ernest Mario sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $3.57, for a total value of $35,700.00. Following the completion of the sale, the director now owns 10,000 shares of the company’s stock, valued at $35,700. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Ernest Mario also recently made the following trade(s):

  • On Thursday, December 14th, Ernest Mario sold 1,967 shares of Tonix Pharmaceuticals stock. The shares were sold at an average price of $3.58, for a total value of $7,041.86.
  • On Thursday, December 21st, Ernest Mario sold 36,967 shares of Tonix Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total value of $129,754.17.

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded up $0.07 on Friday, hitting $3.52. The stock had a trading volume of 65,775 shares, compared to its average volume of 58,735. The firm has a market cap of $26.91, a P/E ratio of -0.74 and a beta of 2.92. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $2.85 and a 12 month high of $9.40.

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Vanguard Group Inc. boosted its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 184,377 shares of the company’s stock after acquiring an additional 41,264 shares during the quarter. Vanguard Group Inc. owned 2.46% of Tonix Pharmaceuticals worth $799,000 at the end of the most recent quarter. Institutional investors own 17.51% of the company’s stock.

Several analysts have recently commented on TNXP shares. ValuEngine upgraded Tonix Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Aegis restated a “buy” rating on shares of Tonix Pharmaceuticals in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Tonix Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $8.33.

TRADEMARK VIOLATION NOTICE: This report was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit